Vera Therapeutics (NASDAQ:VERA) Given New $125.00 Price Target at HC Wainwright

Vera Therapeutics (NASDAQ:VERA) had its price target boosted by HC Wainwright from $110.00 to $125.00 in a report published on Wednesday morning, MarketBeat.com reports. They currently have a buy rating on the stock.

VERA has been the topic of a number of other reports. Evercore set a $91.00 price objective on Vera Therapeutics in a research note on Friday, May 15th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a report on Wednesday, March 11th. Finally, TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.58.

Vera Therapeutics Stock Down 1.2%

VERA opened at $42.43 on Wednesday. The company has a 50 day moving average of $36.40 and a 200 day moving average of $41.16. The company has a market cap of $3.05 billion, a PE ratio of -7.66 and a beta of 0.92. Vera Therapeutics has a 12 month low of $19.07 and a 12 month high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the previous year, the firm posted ($0.81) earnings per share. On average, sell-side analysts expect that Vera Therapeutics will post -6.23 EPS for the current year.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total transaction of $701,705.00. Following the completion of the sale, the chief executive officer directly owned 198,244 shares in the company, valued at $7,519,394.92. This represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 59,951 shares of company stock valued at $2,392,387 over the last ninety days. Insiders own 15.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC grew its position in Vera Therapeutics by 26.7% during the 1st quarter. Janus Henderson Group PLC now owns 17,658 shares of the company’s stock valued at $710,000 after purchasing an additional 3,723 shares during the last quarter. ADAR1 Capital Management LLC raised its holdings in Vera Therapeutics by 8.8% in the first quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company’s stock worth $645,000 after buying an additional 1,300 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Vera Therapeutics by 31.5% in the first quarter. California State Teachers Retirement System now owns 49,737 shares of the company’s stock worth $2,001,000 after buying an additional 11,907 shares in the last quarter. Royal Bank of Canada lifted its stake in shares of Vera Therapeutics by 190.6% in the first quarter. Royal Bank of Canada now owns 19,987 shares of the company’s stock worth $804,000 after buying an additional 13,108 shares in the last quarter. Finally, Quantinno Capital Management LP grew its holdings in shares of Vera Therapeutics by 72.6% during the first quarter. Quantinno Capital Management LP now owns 25,639 shares of the company’s stock valued at $1,031,000 after buying an additional 10,784 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics News Summary

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: The FDA approved TRUTAKNA for primary IgA nephropathy, making it the first and only available therapy targeting both BAFF and APRIL for this kidney disease. Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy
• Positive Sentiment: Multiple reports said the approval triggered a sharp move in the stock, with investors viewing the drug approval as a key commercial catalyst for Vera Therapeutics. US FDA approves Vera’s kidney disease drug
• Positive Sentiment: Analysts responded favorably after the approval, including HC Wainwright raising its price target to $125 and Bank of America lifting its target to $70, reinforcing expectations for meaningful upside if TRUTAKNA gains traction.
• Neutral Sentiment: Wedbush also increased its price target to $43 and kept a neutral rating, suggesting the approval improved sentiment but left some analysts more cautious on valuation.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.